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ABSTRACT  
Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple 
sclerosis exhibiting neuroinflammation, axonal damage and demyelination, further 
characterized by T- and B-cell responses to myelin oligodendrocyte glycoprotein. 
Pharmacological manipulation of phosphodiesterases (PDEs) provokes profound anti-
inflammatory responses through modulation of cAMP levels. The PDE4B subfamily has 
been related to the inflammatory immune response in mice and PDE4 inhibition 
produces amelioration of the clinical signs and delayed onset in the EAE model. 
Analyses of the expression of the mRNA coding for PDE4B splice variants revealed an 
upregulation of PDE4B2 in the brainstem and spinal cord of EAE mice which correlated 
with forkhead box P3 (FoxP3) and transforming growth factor beta (TGF-) mRNAs 
expression in a score-dependent manner. The increase observed for the PDE4B protein 
was mainly found in antigen-presenting cells (APCs) such as dendritic cells and 
microglia/macrophages, in areas with high cellular infiltration. Unexpectedly, PDE4B-/- 
mice showed an earlier onset of the disease compared to wildtype mice. The results 
point to a possible role of the PDE4B enzyme and in particular the PDE4B2 splice 
variant during EAE pathogenesis, probably by modulating cAMP levels in APCs, 
consequently influencing the cytokine environment important for T-cell 
differentiation. 
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1. Introduction 
Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple 
sclerosis (MS) that is induced by active immunization against myelin antigens in 
genetically susceptible mice strains and reproduces the immunopathology seen in 
many MS cases (Swanborg 1995). Several days after immunization, immune cells start 
to infiltrate the CNS and microglial cells are activated, predominantly affecting the 
spinal cord but also other brain structures like the cerebellum and the optic tract 
(Brown and Sawchenko 2007). This is followed by axonal damage and demyelination 
(Soulika et al., 2009).  
 The EAE mouse model is characterized by T- and B-cell responses to myelin 
oligodendrocyte glycoprotein (Iglesias et al., 2001). Depending on the composition of 
the inflammatory environment, differentiation of T-helper (Th)-cells is directed 
towards effector or regulatory T-cells. Several groups have addressed the involvement 
of Th17-positive cells as autoimmune effectors in EAE and of (Foxp3)+cells as 
regulatory T-cells (for review see (Korn et al., 2007; Langrish et al., 2005). Cytokines 
like transforming growth factor beta (TGF-β) and interleukin-6 (IL-6) are known to 
affect the course of differentiating T-cells (Fallarino et al., 2010; Tzartos et al., 2008). 
 Pharmacological manipulation of cAMP levels using specific PDE4 inhibitors 
provoke profound anti-inflammatory responses (Nielson et al., 1990; Torphy 1998), for 
example, suppression or stimulation of cytokine production (Jin and Conti 2002; 
Sommer et al., 1995), and inhibition of T-cell proliferation (Banner and Trevethick 
2004). In the EAE model, amelioration of the clinical signs and delayed onset is 
observed after PDE4 inhibition with rolipram (Folcik et al., 1999; Moore et al., 2006; 
Sommer et al., 1995). The PDE4B gene has been related to the inflammatory response 
in mouse monocytes and macrophages (Jin et al., 2005a) and previous publications by 
our group have shown that the PDE4B mRNA splice variant PDE4B2 is upregulated in 
cellular infiltrates of EAE rat brains (Reyes-Irisarri et al., 2007). Furthermore, during 
innate inflammation the expression of both PDE4B2 and PDE4B3 mRNAs are altered 
(Johansson et al., 2011;  2012b), suggesting a possible role of these enzymes in 
regulating the cytokine environment during neuroinflammation. 
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 The distinct cellular distribution of PDE4 subfamily mRNAs and their presence 
in the cellular infiltrates in the rat EAE model prompted us to further characterize their 
alterations and the cellular locations of the PDE4B enzyme during the course of EAE in 
mice. This information provides important aspects for the development of PDE4 
specific inhibitors in order to treat MS and other inflammatory diseases. 
 Here we present the anatomical localization of changes in PDE4B and PDE4B 
splice variants expression along the course of EAE in mice spinal cord and brain. A 
specific upregulation of the PDE4B2 mRNA was detected from the spinal cord 
extending toward the rostral parts of the brainstem. In addition, we analyzed the 
presence of the PDE4B enzyme in different infiltrating cell populations. Correlation 
between cytokine transcription and the PDE4B2 mRNA was observed in a score-
dependent manner. To further elucidate the role of PDE4 subfamilies during the 
neuroinflammatory response in the EAE model we performed an initial study with 
PDE4A-/- and PDE4B-/- mice. 
2. Material and methods  
2.1 Mice 
Six-week-old female C57BL/6J mice (15-20 g) were purchased from Charles River 
Laboratories (Lyon, France). The generation of mice deficient in PDE4B and PDE4A has 
been described previously (Jin et al., 1999; Jin et al., 2005b; Jin and Conti 2002). The 
experiments reported in figure 5 were performed in the laboratory of Dr M. Conti 
(Department of Obstetrics and Gynecology, University of California, San Francisco, 
California 94143, USA) with wild-type (PDE4A+/+, PDE4B+/+) and PDE4A-/-, PDE4B-/- . For 
knockout mice offspring used in the experiments were derived from mating of the 
corresponding heterozygous. Genotype was determined by Southern blot analysis of 
genomic DNA. Every effort was made to minimize the number of animals used and 
their suffering. The mice were maintained on a 12-h light/dark cycle at a constant 
environmental temperature with free access to food and water in their home cages. 
All experimental procedures followed the European Communities Council Directive of 
November 24, 1986 (86/609/EEC). The individual protocols were approved by the 
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respective committees at the University of California, San Francisco, USA and by the 
ethic committee of the University of Barcelona and of the Generalitat de Catalunya.  
2.2 EAE induction and treatment  
EAE was induced by subcutaneous immunization of female mice with 100μg MOG35-55 
peptide (Sigma-Aldrich, Steinheim, Germany) in 100μl CFA (Sigma-Aldrich) enriched 
with Mycobacterium tuberculosis (Difco, Detroit, MI, USA) on day 0, followed by 200ng 
of pertussis toxin injected intraperitoneally on days 0 and 2. “CFA control mice” 
received CFA and pertussis toxin, but no MOG35-55 peptide. 
Animals were weighed and examined daily and the severity of their clinical disease was 
graded using a five-point scale: Grade 0 = no disability; 1 = a flaccid tail; 2 = a mild but 
definite weakness of one or both hind legs; 3 = moderate paraparesis of one hind leg; 
4 = no hind leg movement; 5 = a moribund state with little or no spontaneous 
movement and impaired respiration (McFarlin et al., 1974). Clinical signs and score 
were monitored up to the day of the sacrifice. Six independent EAE groups were used 
in this study. 
2.3 Tissue preparation 
Brain and spinal cord were removed, rapidly frozen on dry ice and stored at -20 °C on 
p.i.  days 10 (n=5), 15 (n=5), 21 (n=20) and 30 (n=8), CFA-injected control mice (n=6) 
and PDE4A-/- (n=4), PDE4B-/- (n=5), and wildtype control mice (n=4).  
2.4 Hybridization probes and in situ hybridization histochemistry 
For in situ hybridization, immunohistochemistry and histology, 14-μm thick coronal 
tissue sections of whole brain  from EAE and CFA-control mice were cut on a 
microtome-cryostat (Microm HM500 OM, Walldorf, Germany), thaw-mounted on 3-
aminopropyltriethoxysilane-coated slides (Sigma-Aldrich), and stored at -20 °C until 
further processing.  
The oligonucleotides complementary to the mRNAs coding for the different PDEs have 
previously been described (Johansson et al., 2011). Oligonucleotide labeling and in situ 
hybridization conditions used have been described elsewhere (Sanabra and Mengod 
2011; Tomiyama et al., 1997). Hybridized sections were either exposed to Biomax-MR 
6 
 
(Kodak, Rochester, NY, USA) or dipped into Ilford K5 nuclear emulsion (Ilfor, Mobberly, 
Cheshire, UK).  
The specificity of the autoradiographic signal obtained by in situ hybridization 
histochemistry experiments was confirmed by performing a series of routine controls 
(Supplementary Figure 3) similar to those previously described (Pompeiano et al., 
1992; Sanabra and Mengod 2011). Furthermore, hybridization with a scramble 
oligonucleotide only produced background hybridization signal 
2.5 Histology 
Brain sections were stained with Luxol Fast Blue (LFB) and cresyl violet for 
demyelinization and infiltrating cells. 
2.6 Immunohistochemistry 
The following antibodies were used: rabbit anti-human CD3 (Dako Cytomation, 
Glostrup, Denmark), rabbit anti-PDE4B (FabGennix, Inc., Frisco, TX, USA), rabbit anti-
Iba1 (Wako, Neuss, Germany) to detect microglia/macrophages, rabbit anti-GFAP 
(DakoCytomation, Glostrup, Denmark) to detect astrocytes; the monoclonal antibodies 
rat anti-MBP (Abcam, Cambridge, UK) to detect oligodendrocytes, rat anti-NIMP-R14 
(Abcam, Cambridge, UK) for neutrophil staining, rat anti-CD11b (AbD Serotec, Oxford, 
UK) for microglia, hamster anti-mouse CD11c (eBioscience, San Diego, CA, USA) and 
mouse anti-SMI32 (Covance, Emeryville, CA, USA) to detect hypophosphorilated 
neurofilaments as neurodegeneration marker. Immunohistochemistry was performed 
as previously described (Johansson et al., 2011). Primary antibodies were incubated at 
37°C o.n. and secondary antibodies or Alexa Fluor® (Molecular Probes, Leiden, The 
Netherlands) at 37°C for 30 minutes. Sections were mounted with VECTASHIELD® + 
DAPI (Vector Laboratories) to stain nuclei.  
2.7 Quantitative RT/PCR 
Total RNA extracted from frozen cervical spinal cords from EAE mice at days 10, 15, 21, 
and 30 and from CFA-injected control animals (1 g) was reverse-transcribed into 
cDNA using the iScript kit (Bio-Rad, Hercules, CA, USA). Gene transcripts were 
quantified by semiquantitative real-time RT-PCR using the iQ SYBR Green Supermix kit 
(Bio-Rad) in triplicate in 25 l reaction volumes. The sequence-specific primers,  
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synthesized by Biomers.net Gmbh (Ulm, Germany), used were as follows: PDE4A 
forward 5’-CTTCTGCGAGACCTGCTCCA-3’; PDE4A reverse 5’-
GAGTTCCCGGTTCAGCATCC-3’;  PDE4B forward 5’-GCCACTGGATGAGAGGAGCA-3’; 
PDE4B reverse 5’-CCTTTTCCGGTCCCTCAGAA-3’; PDE4B2 forward 5’-
CGGCAAGCAAACAATGAAGG-3’; PDE4B2 reverse 5’-CTGGCCATAGCCGAGTCTCC-3’; 
PDE4B3 forward 5’-GTGTGTAACTTGCAGACAAACCCC-3’; PDE4B3 reverse 5’-
ATCAGGCTGCCTTTGCCTCT-3’; PDE4D forward 5’-ACCGCCAGTGGACGGACCGGA-3’; 
PDE4D reverse 5’-CATGCCACGCTCCCGCTCTCGG-3’; IL-17A forward 5’-
GAAGCTCAGTGCCGCCA-3’; IL-17A reverse 5’-TTCATGTGGTGGTCCAGCTTT-3’; FoxP3 
forward 5’-GGCCCTTCTCCAGGACAGA-3’; FoxP3 reverse 5’-CTGATCATGGCTGGGTTGT-
3’; TNF-α forward 5’-TGATCCGCGACGTGGAA-3’; TNF-α reverse 5’-
ACCGCCTGGAGTTCTGGAA-3’; interferon-γ (IFN-γ) forward 5’-
TGCTGATGGGAGGAGATGTCT-3’; IFN-γ reverse 5’- TTTCTTTCAGGGACAGCCTGTT-3’; IL-
1β forward 5’-TGGTGTGTGACGTTCCCATTA-3’; IL-1β reverse 5’-
CAGCACGAGGCTTTTTTGTTG-3’; IL-6 forward 5’- CCAGTTTGGTAGCATCCATC-3’; IL-6 
reverse 5’-CCGCAGAGGAGACTTCACAG-3’; cyclooxygenase-2 (COX-2) forward 5’- 
GCCACCAACAATGGCAACA-3’; COX-2 reverse 5’- CGTACCGGATCAGCTGTGAATT-3’; 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) forward 5’-
TGGTGAAAAGGACCTCTCGAA-3’; and HPRT reverse 5’- TCAAGGGCATATCCAACAACA-3’. 
The n-fold differential expression was determined by the comparative cycle threshold 
(CT) method (2–ΔΔCT), normalized to the HPRT endogenous reference gene. Negative 
control experiments were performed without the addition of template cDNA. End 
reaction products were visualized using SYBRSafe (Invitrogen) in 3.4% agarose gels to 
verify the correct product sizes. 
2.8 Lymphocyte stimulation and ELISA 
In vitro stimulation responses of spleen cells were determined using a standard 
microtiter assay. Briefly, spleen cells isolated from EAE wt and KO mice 21 days p.i.  
were cultured in 96-well, flat bottom tissue culture plates at 4x105 cells per well  for 4h 
in RPMI medium. Cells were then stimulated using 25 g of MOG35-55 for 24, 48, 72 and 
120 hours at 37ºC in 5% CO2. Supernatants were collected, and analyzed to detect 
cytokine levels by Mouse TNF alpha ELISA Ready-SET-Go!® (eBioscience), Mouse IL-4 
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ELISA Ready-SET-Go!® (eBioscience), BD OptEIA TM Mouse IFN- ELISA Kit II (BD 
Biosciences, San Diego, CA, USA) and Quantikine® Mouse IL-17 Immunoassay (R&D 
Systems, Inc., Minneapolis, MN, USA). 
2.9 Figure preparation 
Photographs of the film autoradiograms of hybridized sections were obtained using a 
Wild 420 macroscope (Leica, Heerbrugg, Germany) equipped with a digital camera 
(DXM1200 F, Nikon, Tokyo, Japan) and ACT-1 Nikon software. Microphotographs of the 
hybridized tissue slides were taken with a Zeiss Axioplan microscope, equipped with a 
digital camera (DXM1200 F, Nikon) with ACT-1 Nikon software and a Darklite 
illuminator (Micro Video Instruments, Avon, MA, USA) to improve the visualization of 
autoradiographic silver grains and capture bright- and dark-field images. Double 
immunofluorescent-labeled sections were photographed in an Olympus BX51 stereo 
microscope equipped with a digital camera (DP71, Olympus, Tokyo, Japan). The figures 
were assembled using Adobe Photoshop (Adobe Systems, San Jose, CA, USA); only 
contrast and brightness were adjusted to optimize the images.  
2.10 Analysis of the results  
Statistical comparisons between EAE and control mice were carried out by separate 
one-way ANOVA followed by post-hoc analysis Bonferroni’s test for day post injection. 
Statistical comparisons using the factors day post-immunization or, using the factors 
inflammatory markers and immunization were carried out by separate two-way 
ANOVA followed by post-hoc Dunnett’s test for day post-immunization and clinical 
score by post-hoc Tukey’s test for inflammatory marker and mice used respectively. 
The correlation analysis was performed by Pearson’s correlation method. All statistical 
analyses were performed in GraphPad Prism 4 (GraphPad Software, San Diego, CA). 
3. Results 
3.1. The chronic model of EAE in C57BL/6J mice 
C57BL/6J mice immunized with MOG35-55 began to show neurological deficits on day 
12-13 post-immunization (p.i.), reaching a peak between days 17 and 21. The chronic 
neurological deficits evaluated as clinical scores are summarized in Supplementary 
Figure 1. Complete Freund’s adjuvant (CFA) control mice showed no clinical score (data 
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not shown). Demyelination and cellular infiltration in CNS were observed in some 
areas of spinal cord and brain by Luxol/Cresyl-Violet staining (Fig 1A, B) and DAPI (Fig. 
1C). Observations with SMI-32 (Fig 1D) and FluoroJadeB (Fig 1E) also confirmed the 
presence of axonal damage and neurodegeneration in our EAE model. 
3.2. PDE4 mRNA expression in the central nervous system of mice with EAE  
We studied the mRNA expression of the three PDE4 subfamilies, PDE4A, PDE4B and 
PDE4D in EAE mouse brainstem and cerebellum (Fig2A-F).  PDE4B and PDE4D mRNAs 
are normally present at high levels in the granular layer of the cerebellum of CFA 
control mice (Fig. 2H, 2I) (Johansson et al., 2012a). PDE4B mRNA showed 
overexpression in EAE mice in a patchy-like manner (Fig. 2B, E, white arrow heads), 
whereas the other two subfamilies presented an unchanged hybridization pattern with 
the disease. We further analyzed the four PDE4B splice variants mRNA expression in 
these animals and observed that the only mRNA upregulated was PDE4B2 (Fig. 2K, O) 
in EAE brain sections, showing a similar pattern to that observed for PDE4B mRNA (Fig. 
2B, E).  
 The anatomical localization of PDE4B2 mRNA in the brainstem and spinal cord 
of EAE mice with established disease, i.e. 30 days p.i., was further determined. The 
upregulation of PDE4B2 mRNA expression is visible as dark patches of 
autoradiographic grains following radioactive in situ hybridization histochemistry at 
several levels of the brainstem of the EAE mouse (Fig. 3A-C), whereas in CFA-treated 
control mice no alterations in the hybridization signal were observed (Fig. 3D-F).  
 We evaluated the mRNA expression levels of the PDE4B2 splice variant in 
mouse brain and spinal cord at different p.i. times (before the onset of EAE at day 10, 
just after the onset of disease at day 15, around the peak at day 21, and at day 30).  
The results obtained in spinal cord sections of EAE and CFA-injected control mice using 
semiquantitative real-time RT-PCR revealed upregulation of PDE4B2 mRNA expression 
that increased with the time after immunization, being statistically significant in 
animals at 30 days p.i. (Fig. 3G). We also observed a significant PDE4B2 mRNA 
upregulation with increasing disease scores at day 30 p.i. (Fig. 3G). Changes in various 
inflammatory markers (tumor necrosis factor –α (TNF-α), IL-6, FoxP3, IL-17, interferon- 
γ (IFN-γ), IL-1β and TGF-β) were also investigated with semiquantitative real-time RT-
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PCR to validate the immune response. All markers were upregulated at day 15 (except 
IFN-γ and IL-6) and at day 21 (data not shown). 
3.3. PDE4B protein expression in the central nervous system of mice with EAE 
In order to determine whether PDE4B2 mRNA upregulation in the EAE mice 
corresponded to an increase in the amount of synthesized protein we incubated tissue 
sections with an antibody against PDE4B and compared them to consecutive spinal 
cord sections hybridized for PDE4B2 mRNA (Fig. 3H). Areas with high amounts of 
inflammatory infiltrates coincided with clear immunostaining of PDE4B+-cells and were 
mainly found close to meninges, aqueduct, 4th ventricle walls and microvessels.  
 We then identified the nature of the cellular infiltrates expressing the PDE4B 
protein. For this, tissue sections were double-stained with the PDE4B antibody and 
with antibodies against microglia/macrophages (CD11b+ and Iba1+-cells), 
oligodendrocytes (MBP+-cells), astrocytes (GFAP+-cells), T-cells (CD3+-cells), 
neutrophils, and dendritic cells (CD11c+-cells) (Fig. 4). We observed that 
microglia/macrophages (Fig. 4 A-F) and dendritic cells (Fig. 4 G-I) partly colocalized 
with PDE4B+-cells. Colocalization between T-cells and PDE4B+-cells was not observed 
(Fig. 4J-L); however, polarization of PDE4B at the contact area between these two cells 
could be detected (inset Fig. 4L). In areas with cell infiltrates oligodendrocytes were 
clearly absent, indicating demyelination (see Supplementary Figure 2). PDE4B protein 
was not observed in infiltrating neutrophiles (see Supplementary Figure 2C). 
Nevertheless, PDE4B expression could be detected at low intensity in some 
oligodendrocytes and astrocytes (see Supplementary Figure 2F, I), which might be 
explained by the expression of PDE4B3 splice variant in these cells (Johansson et al., 
2011). 
3.4 The chronic model of EAE in PDE4A-/- and PDE4B-/- mice: EAE progression and 
neuroinflammatory response 
In order to further examine the role of PDE4 enzymes in EAE, we immunized PDE4A-/- 
and PDE4B-/- mice. Our preliminary results show an earlier onset of the disease for 
PDE4B-/- mice and a trend to lower clinical score for the PDE4A-/- mice group compared 
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to wt. PDE4B-/- mice start to show neurological deficits around day 10 p.i., reaching a 
maximum at day 14 p.i. (Fig. 5A). 
 The expression levels for several inflammatory cytokines and for some 
transcription factors (markers of different T-cell subsets) were determined to evaluate 
the inflammatory response. In the PDE4A-/- mice group a significant decrease in mRNA 
expression for TNF- and IFN- was observed compared to the wt group (Fig. 5B). We 
also detected a significant downregulation of Rorc transcription factor mRNA 
expression in PDE4A-/- mice (Fig. 5C).  The PDE4B-/- group showed a significant decrease 
in mRNA expression of TGF- and Rorc (Fig. 5C). Furthermore, a tendency to 
downregulation of IFN- and TNF- mRNA expression and a trend to upregulation of 
the proinflammatory cytokine IL-6 (Fig. 5B) were observed in the PDE4B-/- mice. 
 The immunological response capacity of leukocytes from knockout mice was 
measured by in vitro stimulation. Compared to wt, no changes in IL-4 production after 
MOG stimulation could be detected at any time point. However, lower levels of IFN- 
production in PDE4B-/- leukocytes were seen, whereas PDE4A-/- splenocytes seemed to 
produce similar levels as the wt group (data not shown). 
 Evaluation of axonal degeneration showed no differences in SMI32 
immunoreactivity in spinal cord tissue sections of knockout and wt mice (data not 
shown).  
3.5 PDE4B2 splice variant in disease severity and cytokine expression 
In view of the results obtained with PDE4B-/- mice in disease severity and differences in 
cytokine expression, we analyzed the correlation between PDE4B2 mRNA and 
inflammatory cytokines or T cell specific transcription factors in our EAE mice at the 
peak of the disease, day 21 after immunization. The mRNA levels for PDE4B2 
correlated significantly (Pearson correlation, R= 0.927; P< 0.05) with clinical scores (Fig. 
6A). The relative mRNA expression of PDE4B2 also revealed statistically significant 
correlations (Pearson correlation) with FoxP3 (R= 0.71; P< 0.001) (Fig. 6B) and with 
TGF- (R= 0.64; P< 0.005) (Fig. 6C). No correlation was found with other inflammatory 
markers such as TNF, IL-17 and IL-6 (data not shown). 
4. Discussion 
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The work presented here shows that the PDE4B subfamily and particularly the PDE4B2 
splice variant was the only PDE4 presenting alterations in the CNS of EAE mice. The 
upregulation of the PDE4B expression was observed as dark patches in areas 
coinciding with cellular infiltrates being the PDE4B enzyme protein localized to 
different antigen presenting cells, such as dendritic cells, microglia and macrophages,. 
Additionally, we show that the PDE4B2 splice variant mRNA correlated with FoxP3 
transcription factor and TGF-β mRNAs in a score-dependent manner. Preliminary 
results reported here, revealed, unexpectedly, that PDEB-/- mice exhibited an earlier 
onset of the disease compared to wildtype mice. 
 PDE4 enzymes have been proposed as targets for anti-inflammatory drugs for 
diseases such as asthma and chronic obstructive pulmonary disease or inflammatory 
bowel disease (Hatzelmann et al., 2010; Spina 2008). Lipopolysaccharide (LPS) 
stimulation of mouse inflammatory cells from PDE4B or PDE4D KO mice induced 
PDE4B mRNA accumulation and increased PDE4 enzymatic activity with no changes in 
cAMP levels in PDE4B KO mice cells, suggesting that PDE4B regulates a minor cAMP 
pool (Jin et al., 2005a; Jin and Conti 2002). In our group we have previously reported a 
selective increase in PDE4B2 mRNA levels in LPS-treated rats (Reyes-Irisarri et al., 
2008) and in brain circumventricular organs of LPS-treated mice (Johansson et al., 
2011). All this together points to the involvement of the PDE4B subfamily in events 
related to neuroinflammation. 
 PDE4B2 mRNA expression is found in many brain areas in both rat (Reyes-
Irisarri et al., 2007) and mouse (Johansson et al., 2011). Upregulation of PDE4B2 mRNA 
expression was observed 2-3 days after the onset of the disease (day 15), and was 
significantly elevated in animals with ongoing EAE in the spinal cord and later 
spreading throughout the posterior brain areas, coinciding with previous results in rats 
(Reyes-Irisarri et al., 2007). The PDE4B protein presented a distribution pattern 
comparable to that observed for infiltrating cells in the EAE brain during disease 
(Brown and Sawchenko 2007) suggesting that these cells might express PDE4B2 at 
elevated levels. The correlation between PDE4B2 mRNA expression and the clinical 
score reported here further supports this assumption, since an advanced clinical score 
is associated with an elevated number of cellular infiltrates (Brown and Sawchenko 
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2007). The increase in PDE4B protein expression, which coincides with the PDE4B2 
mRNA upregulation in areas with high infiltration of immune cells and morphological 
damage and not in other brain areas, might be a reflection of a selective regulation of 
the enzyme to control cAMP levels. This exclusive PDE4B increment in the brain 
infiltrates could also be important for the local regulation of cytokine secretion and the 
antigen presentation process as explained below.  
 In the EAE model, peripheral antigen-presenting cells (APCs) like dendritic cells  
and macrophages associated with the meninges and CNS blood vessels (Greter et al., 
2005; Sospedra and Martin 2005) are known to infiltrate the CNS where lymphocytes 
are reactivated by the main APC population in the brain parenchyma, microglia, as 
reviewed by Almolda and coworkers ( 2011). Activation/suppression of APCs and 
regulation of the cytokine environment are known to be controlled by cAMP levels 
(Fassbender et al., 2010; Kambayashi et al., 2001). Therefore the upregulation of 
PDE4B2 mRNA that we report here, in areas with high amount of cellular infiltrates 
and around the microvessels, together with the role of cAMP in the antigen 
presentation process (Fallarino et al., 2010) suggest a relation between the PDE4B2 
presence and APCs in the CNS. This is further supported by the colocalization between 
the PDE4B enzyme and different APC populations (dendritic cells, microglia and 
macrophages) presented here. 
 The undetectable levels of PDE4B protein expression in infiltrating T-cells 
reported in this work contrasts with the previous report on PDE4B2 mRNA localization 
in these cells in the Lewis EAE rat model (Reyes-Irisarri et al., 2007) leaving the role 
played by this enzyme during T-cell regulation still open. Nevertheless, the polarization 
observed for PDE4B protein at the contact area between CD3+-cells and PDE4B+-cells 
further supports a role of this enzyme during the antigen-presenting process in the 
CNS. In fact, Arp and coworkers ( 2003) have described the participation of PDE4B in T-
cell receptor activation in the immunological synapse in cell cultures. 
 The amelioration of the clinical signs and delayed onset of EAE described after 
PDE4 inhibition (Folcik et al., 1999; Martinez et al., 1999; Moore et al., 2006; Sommer 
et al., 1995) prompted us to use PDE4B and PDE4A knockout mice to analyze this 
published data with a non-pharmacological approach. Considering the fact that PDE4B 
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is the only isoform altered in the EAE model, our working hypothesis was that EAE in 
the PDE4B-/- mice would result in an improved outcome of clinical symptoms in these 
animals. However, our preliminary results revealed that those mice showed a worse 
condition and an earlier disease onset. The response obtained in our preliminary 
experiments with the knockout mice underlines different functions of each PDE4 
subfamily in EAE, since distinct responses were observed in the two different knockout 
groups further inferring a possible role of the PDE4B isoform in the neuroinflammatory 
response.  Thus, these results are in clear disagreement with literature reports 
concerning the effects of pharmacological inhibition of PDE4. Two factors may 
influence this apparent contradiction with our data: i) When a pharmacological 
treatment with PDE4 inhibitors (i.e. rolipram) is performed, this is made during a 
relatively short period of time at a precise moment of the “adult” life of the animal and 
ii) the inhibition of the PDE4-family with molecules such as rolipram, implies the 
inhibition of the four PDE4 subfamilies, all showing a tissue- and cell-specific 
distribution (Cherry and Davis 1999;  2002b; Miró et al., 2002a; Reyes-Irisarri et al., 
2007). Furthermore, a direct comparison of the disease development between PDE4 
inhibitor-treated EAE mice and EAE PDE4B-/- mice is difficult given the absence of this 
enzyme in the PDE4B knockout mice throughout the animal´s life, making a direct 
comparison of the disease development between the PDE4 inhibitor-treated EAE mice 
with EAE PDE4B KO mice difficult. The unexpected preliminary results obtained here 
with the EAE PDE4B-/- mice point to the importance of developing isoform-specific 
PDE4B inhibitors opening new promising research lines to investigate the role played 
by the PDE4 subfamilies. 
T-cell populations that have a crucial role in the EAE model are Th1- and Th17-positive 
cells (Komiyama et al., 2006; Tzartos et al., 2008; Zamvil and Steinman 1990). These 
immune cells infiltrate and attack oligodendrocytes, activate resident microglia and 
astrocytes, leading to demyelination and axonal damage in the EAE model (Lassmann 
et al., 2001; Soulika et al., 2009). Another T-cell population, FoxP3+Treg cells, regulates 
the immunological response e.g. by secretion of anti-inflammatory cytokines (Korn et 
al., 2007). The conversion of T-cells into the more favorable Foxp3+ T-regs or the 
hazardous Th17+-cells is dependent on the inflammatory environment where TGF-β 
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and IL-6 play a role in the balance between these two cell populations (Deshpande et 
al., 2007; Fallarino et al., 2010; Korn et al., 2007). The presence of both IL-6 and TGF-β 
induces Th17 differentiation from naïve T cells (Mangan et al., 2006); however, TGF-β 
alone has immunosupressor properties and can induce Tregs FoxP3+ cells generation 
(Li et al., 2006).  
In the PDE4B-/- mice spinal cord we observed a tendency for upregulation of IL-6 mRNA 
whereas TGF- mRNA is expressed at lower levels than in wt. This change in the 
balance between these two cytokines could result in higher Th17 cells differentiation 
producing the earlier onset of the disease in the PDE4B-/- mice. In fact, PDE4B-/- mice 
spleen cells seem to produce significant higher amounts of IL-17 after MOG 
stimulation in vitro (data not shown).  
The correlation described between PDE4B2 mRNA upregulation and FoxP3+ and TGF-β 
expression in EAE mice, together with the lack of correlation with IL-6 opens new lines 
of investigation on the possible role of this PDE4B splice variant in Treg cells 
differentiation, possibly by modulating the cytokine environment. Changes in IL-6 
production and TGF-β mRNA expression have been described in APCs such as 
microglia/macrophages following brain injury (Delfino and Walker 1999; Fallarino et 
al., 2010; Hashioka et al., 2007), cells where we found an increase of PDE4B. 
5. Conclusion 
We have shown that in EAE mice a specific upregulation of the PDE4B2 splice variant 
mRNA takes place in a score and time-dependent manner, as a patchy pattern 
throughout the spinal cord and the brainstem. The PDE4B upregulation occurs mainly 
in antigen presenting cells in areas with high amounts of brain infiltrates where it 
might modulate cAMP levels and consequently the local cytokine secretion important 
for T-cell differentiation.  
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Figure Captions 
Figure 1. Histopathological analysis of EAE spinal cord at 30 days p.i.. (A) Tissue 
sections stained with Luxol Fast Blue/Cresyl-Violet for myelin and cellular nuclei 
respectively. (B) The strong cellular invasion observed here was found associated with 
demyelination, and also coinciding with increased DAPI staining (C). (D) Axonal damage 
(arrowhead) shown by SMI32 immunostaining; and (E) Fluorojade B staining to detect 
neurodegeneration (arrowheads). Scale bars = 500 μm (A), 100 μm (B=C; D=E). 
Figure 2. PDE4 mRNAs expression in EAE mice 21 days after immunization. 
Macroscopic photographs from film autoradiograms of coronal posterior brain 
sections hybridized with 33P-labeled oligonucleotides to visualize PDE4A (A, D), PDE4B 
(B, E) and PDE4D (C, F) mRNAs. CFA control mice brainstem sections hybridized to 
visualize PDE4A (G), PDE4B (H) and PDE4D (I) mRNAs show that all three are normally 
present in the granular layer of the cerebellum.   Lower panel show the expression of 
PDE4B splice variants in EAE mice brains: PDE4B1 (J, N), PDE4B2 (K, O), PDE4B3 (L, P) 
and PDE4B4 (M, Q). Note the upregulation as scattered hybridization pattern for 
PDE4B mRNA (white arrowheads) in EAE animals (B, E) that corresponds only to the 
PDE4B2 splice variant mRNA (K, O).  Cb: cerebellum; GrL: granular layer of the 
cerebellum, wm: white matter. Scale bars = 2mm.  
Figure 3. PDE4B2 splice variant mRNA expression in EAE mice brain. Macroscopic 
photographs of hybridized coronal brainstem sections from film autoradiograms show 
an upregulation (scattered pattern) of PDE4B2 mRNA in EAE mice 30 days after 
immunization (A-C) compared to control mice immunized with CFA without MOG35-55. 
(D-F). (G) Expression of PDE4B2 mRNA in spinal cord of EAE mice at 10, 15, 21 and 30 
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days p.i.  (total n=38) and for clinical scores at 21 and 30 days p.i.  (n=28). PDE4B2 
mRNA expression was determined by semiquantitative real-time RT-PCR (corrected for 
the housekeeping gene HPRT). Error bars indicate SEM value. Two-way ANOVA 
analysis followed by Dunnett’s post-test shows significant difference between CFA 
control and EAE mice 30 days p.i. ; *, P< 0.05. (H) PDE4B expression in the spinal cord 
of a mouse with EAE 30 days after immunization. PDE4B+-cells (red) were observed in 
areas with high amounts of inflammatory cells, shown with DAPI counterstaining 
(blue). High-magnification dark-field microphotograph of emulsion-dipped section 
show PDE4B2 mRNA upregulation pattern visualized by in situ hybridization (clusters of 
silver grains). Aq: aqueduct; Cb: cerebellum; CEnt: caudomedial entorhinal cortex; GrL: 
granular layer of the cerebellum; IC: inferior colliculus; SC: superior colliculus; wm: 
white matter. Scale bar = 200 μm (A-F) and 50 μm (H).  
Figure 4. PDE4B protein in antigen-presenting cells and T cells in spinal cord sections 
from 30 days p.i. EAE mice. PDE4B protein was observed in areas with inflammatory 
infiltrates. Dual immunostaining of PDE4B+-cells (red) and (A-C) CD11c+-dendritic cells 
(green), (D-F) CD11b+-microglia/macrophages (green), (G-I) Iba1+-
microglia/macrophages (green), and (J-L) CD3+-T cells (green) and DAPI+-nuclei (blue). 
Colocalization of both proteins is indicated by white arrowheads. Note the polarization 
of PDE4B (red) at the contact area between the cells (arrow) in the inset (L). Scale bars 
= 50 μm and 10 μm.  
Figure 5. Clinical evaluation and neuroinflammatory response of EAE PDE4A-/- and 
PDE4B-/- mice. (A) Mean  SD clinical score as a function of days after immunization 
with the MOG35-55 peptide.  Significant earlier onset was observed for PDE4B-/- mice 
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compared to wt, *, P< 0.05; **, P< 0.01 by separate one-way analyses of variance 
followed by Bonferroni’s test. Expression of inflammatory cytokines (B)  and T cell 
specific transcription factors (C)  mRNAs in PDE4A-/- (n=5), PDE4B-/- (n=6) and wt (n=4), 
EAE mice 21 days p.i. . mRNA expression was determined by semiquantitative real-
time RT-PCR (corrected for the housekeeping gene HPRT). Error bars indicate SEM 
value. Two-way ANOVA analysis followed by Tukey’s post-test shows significant 
difference between wt and knockout EAE mice; *, P< 0.05; **, P< 0.01.  
Figure 6. Correlation between PDE4B2 expression with EAE clinical score or with 
inflammatory markers in EAE spinal cord at 21 days p.i.. mRNA expression was 
determined by semiquantitative real-time RT-PCR. HPRT was used as an internal 
control for normalization of each gene analyzed. The correlation of the mRNA 
expression of each individual mice was assessed by Pearson correlation analysis, and 
was as follows: (A) clinical score (R= 0.927; P< 0.05); (B) FoxP3 (R= 0.71; P< 0.001); (C) 
TGF-β (R= 0.643; P< 0.005). Each dot represents one mouse. R: correlation coefficient. 
SUPPLEMENTARY Fig. 1. Clinical evaluation of EAE in C57BL/6J mice. Mean  SD 
clinical score as a function of days after immunization with the MOG35-55 peptide. Six 
independent EAE groups were used with a total of 38 mice. Clinical Score; 0 = no 
disability, 1 = flaccid tail, 2 = a mild but definite weakness of one or both hind legs, 3 = 
moderate paraparesis of one hind leg, 4 = no hind leg movement, 5 = a moribund state 
with little or no spontaneous movement and impaired respiration.  
 
SUPPLEMENTARY Fig. 2. Immunohistochemistry for glial cells and neutrophils in spinal 
cord sections from a 30 days p.i. EAE mouse. PDE4B protein was observed in areas 
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with inflammatory infiltrates (A, D, G). Double immunostaining of PDE4B+-cells (A, D, 
G) with neutrophils (B), GFAP+-astrocytes (E) and MBP+-oligodendrocytes (I).  (C, F, I) 
are the corresponding merged images. Scale bar = 50 μm. 
 
SUPPLEMENTARY Fig.3. Specificity controls of the hybridization signal obtained with 
PDE4B2 oligonucleotides. Coronal sections from healthy mice were hybridized with 
33P-labeled PDE4B2 oligonucleotide. Thermal stability of the hybrids was examined by 
washing at 60ºC (A), 80ºC (B) and 90ºC (C). Hybridization signal was maintained after 
co-hybridizing with an excess of another PDE4B2 oligonucleotide probe 
complementary to a different domain of the mRNA molecule (D). No hybridization 
signal remained after co-hybridizing the labeled oligonucleotide with an excess of the 
same unlabeled oligonucleotide (E).  F and G are dark-field photomicrographs from 
nuclear emulsion dipped sections from EAE mice spinal cord sections hybridized with 
PDE4B2 oligonucleotide (F) and with a scramble oligonucleotide (G). Cellular infiltrates 
expressing high amounts of PDE4B2 mRNA can be clearly seen as white bright spots 
(white arrowheads) in the white matter, whereas a similar zone of the cerebellum 
hybridized with the scramble probe only background hybridization signal is seen.  GL: 
granular layer of the cerebellum; wm: white matter. Scale bars = 1mm (A-E) and 50m 
(F-G). 
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